Terns Pharmaceuticals, Inc. EBIT Margin

EBIT Margin of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Margin growth rates and interactive chart. Earnings before interest and taxes margin is an indicator of a company's profitability. Calculated as earnings before interest and taxes (EBIT) divided by revenue. It is useful for comparison of companies with different debt levels and tax rates. And EBIT margin gives a clear picture about the underlying profitability of a company's core operations. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes.


Highlights and Quick Summary

  • EBIT Margin for the quarter ending March 31, 2022 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT Margin decreased by NaN%
  • Annual EBIT Margin for 2021 was -9972.0% (a -Infinity% decrease from previous year)
  • Annual EBIT Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual EBIT Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month EBIT Margin ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing EBIT Margin decreased by NaN% year-over-year
Trailing EBIT Margin for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Margin of Terns Pharmaceuticals, Inc.

Most recent EBIT Marginof TERN including historical data for past 10 years.

Interactive Chart of EBIT Margin of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0%
2021 -1387.8% 0.0% 0.0% 0.0% -9972.0%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0%
2018 0.0%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.